TY - JOUR
T1 - Testosterone and androstenedione are positively associated with anti-Müllerian hormone in premenopausal women
AU - Islam, Rakibul M.
AU - Bell, Robin J.
AU - Skiba, Marina A.
AU - Davis, Susan R.
N1 - Funding Information:
The authors would like to acknowledge the contribution of Sullivan Nicolaides Pathology, Bowen Hills, Queensland, Australia for the performance of the Access anti‐Müllerian hormone assay. This study was supported by the philanthropic grants from the Norman Beischer Medical Research Foundation and the Grollo Ruzzene Foundation, Melbourne Australia, which had no role in the study design, conduct or reporting. Dr. Davis is an NHMRC Senior Principal Research Fellow (Grant No. 1135843).
Funding Information:
Susan R. Davis has been paid for developing and delivering educational presentations for Besins Healthcare, Abbott Chile, BioFemme and Pfizer Australia has been on Advisory Boards for Theramex, Abbott Laboratories, Astellas, Mayne Pharmaceuticals and Roche Diagnostics and has been a consultant to Lawley Pharmaceuticals and Que Oncology and has received institutional research funding from Que Oncology and Ovoca. There are no other relationships or activities that could appear to have influenced the submitted work.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Objective: To document associations between anti-Müllerian hormone (AMH) and circulating androgens in nonhealthcare-seeking premenopausal women. Design: Community-based, cross-sectional study. Setting: Eastern states of Australia. Participants: Women aged 18–39 years not using systemic hormones, not pregnant or breastfeeding within 3 months, and not postmenopausal. Measurements: AMH, measured by the Beckman Access 2, 2 site immunometric assay from fresh samples, and testosterone, androstenedione, dehydroepiandrosterone (DHEA) and 11-oxygenated C19 steroids, measured by liquid chromatography–tandem mass spectrometry. Results: Data were available for 794 women, median age of 33 years (range: 18–39). 76.1% were of European ancestry and 48.2% were parous. Serum AMH was positively associated with testosterone (rho =.29, p <.001) androstenedione (rho =.39, p <.001) and DHEA (rho =.10, p =.005) but not 11-ketoandrostenedione or 11-ketotestosterone. When adjusted for age, body mass index and smoking, using quantile regression, independent positive associations remained between AMH and testosterone (β coefficient: 20.90, 95% confidence interval [CI]: 13.79–28.03; p <.001) and androstenedione (β coefficient: 5.90, 95% CI: 3.76–8.03; p <.001). The serum concentration of testosterone was greater at the top AMH quintile than other quintiles (0.56 nmol/L [range: 0.21–1.90] vs. 0.36 nmol/L [range: 0.13–0.87]; p =.001) in women with self-reported polycystic ovary syndrome. Conclusions: The positive associations between serum testosterone and androstenedione and AMH in premenopausal women is consistent with androgens directly or indirectly influencing AMH production during follicular development. As the highest AMH concentrations are most likely to be seen in women with multifollicular ovaries, it would be expected that women with multifollicular ovaries would have higher serum testosterone. Therefore, whether hyperandrogenemia and multifollicular ovaries should be considered independent characteristics of polycystic ovary syndrome warrants review.
AB - Objective: To document associations between anti-Müllerian hormone (AMH) and circulating androgens in nonhealthcare-seeking premenopausal women. Design: Community-based, cross-sectional study. Setting: Eastern states of Australia. Participants: Women aged 18–39 years not using systemic hormones, not pregnant or breastfeeding within 3 months, and not postmenopausal. Measurements: AMH, measured by the Beckman Access 2, 2 site immunometric assay from fresh samples, and testosterone, androstenedione, dehydroepiandrosterone (DHEA) and 11-oxygenated C19 steroids, measured by liquid chromatography–tandem mass spectrometry. Results: Data were available for 794 women, median age of 33 years (range: 18–39). 76.1% were of European ancestry and 48.2% were parous. Serum AMH was positively associated with testosterone (rho =.29, p <.001) androstenedione (rho =.39, p <.001) and DHEA (rho =.10, p =.005) but not 11-ketoandrostenedione or 11-ketotestosterone. When adjusted for age, body mass index and smoking, using quantile regression, independent positive associations remained between AMH and testosterone (β coefficient: 20.90, 95% confidence interval [CI]: 13.79–28.03; p <.001) and androstenedione (β coefficient: 5.90, 95% CI: 3.76–8.03; p <.001). The serum concentration of testosterone was greater at the top AMH quintile than other quintiles (0.56 nmol/L [range: 0.21–1.90] vs. 0.36 nmol/L [range: 0.13–0.87]; p =.001) in women with self-reported polycystic ovary syndrome. Conclusions: The positive associations between serum testosterone and androstenedione and AMH in premenopausal women is consistent with androgens directly or indirectly influencing AMH production during follicular development. As the highest AMH concentrations are most likely to be seen in women with multifollicular ovaries, it would be expected that women with multifollicular ovaries would have higher serum testosterone. Therefore, whether hyperandrogenemia and multifollicular ovaries should be considered independent characteristics of polycystic ovary syndrome warrants review.
KW - AMH
KW - androgens
KW - anti-Mullerian hormone
KW - folliculogenesis
UR - http://www.scopus.com/inward/record.url?scp=85115076336&partnerID=8YFLogxK
U2 - 10.1111/cen.14592
DO - 10.1111/cen.14592
M3 - Article
C2 - 34524701
AN - SCOPUS:85115076336
SN - 0300-0664
VL - 95
SP - 752
EP - 759
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 5
ER -
